vs
EXACT SCIENCES CORP（EXAS）与Snap Inc（SNAP）财务数据对比。点击上方公司名可切换其他公司
Snap Inc的季度营收约是EXACT SCIENCES CORP的1.7倍（$1.5B vs $878.4M），Snap Inc净利率更高（-5.8% vs -9.8%，领先4.0%），EXACT SCIENCES CORP同比增速更快（23.1% vs 12.1%），Snap Inc自由现金流更多（$286.0M vs $120.4M），过去两年EXACT SCIENCES CORP的营收复合增速更高（17.4% vs 11.2%）
Exact Sciences是总部位于美国威斯康星州麦迪逊的分子诊断企业，专注于早期癌症检测领域。公司核心产品覆盖结直肠癌筛查与预防场景，其中Cologuard是全球首个获批的结直肠癌粪便DNA检测产品，同时还提供其他多种癌症的筛查服务及精准肿瘤检测解决方案。
Snap Inc.是一家美国科技企业，2011年9月16日由埃文·斯皮格尔、鲍比·墨菲和雷吉·布朗联合创立，总部位于加利福尼亚州圣莫尼卡。公司核心产品包括社交应用Snapchat、智能眼镜Spectacles、虚拟形象工具Bitmoji以及营销推广解决方案SnapBoost，2016年9月24日由原Snapchat Inc.更名为现名，覆盖社交、智能硬件等多元业务领域。
EXAS vs SNAP — 直观对比
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $878.4M | $1.5B |
| 净利润 | $-86.0M | $-89.0M |
| 毛利率 | 70.1% | 56.5% |
| 营业利润率 | -9.4% | -4.9% |
| 净利率 | -9.8% | -5.8% |
| 营收同比 | 23.1% | 12.1% |
| 净利润同比 | 90.1% | 36.3% |
| 每股收益（稀释后） | $-0.45 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q1 26 | — | $1.5B | ||
| Q4 25 | $878.4M | $1.7B | ||
| Q3 25 | $850.7M | $1.5B | ||
| Q2 25 | $811.1M | $1.3B | ||
| Q1 25 | $706.8M | $1.4B | ||
| Q4 24 | $713.4M | $1.6B | ||
| Q3 24 | $708.7M | $1.4B | ||
| Q2 24 | $699.3M | $1.2B |
| Q1 26 | — | $-89.0M | ||
| Q4 25 | $-86.0M | $45.2M | ||
| Q3 25 | $-19.6M | $-103.5M | ||
| Q2 25 | $-1.2M | $-262.6M | ||
| Q1 25 | $-101.2M | $-139.6M | ||
| Q4 24 | $-864.6M | $9.1M | ||
| Q3 24 | $-38.2M | $-153.2M | ||
| Q2 24 | $-15.8M | $-248.6M |
| Q1 26 | — | 56.5% | ||
| Q4 25 | 70.1% | 59.1% | ||
| Q3 25 | 68.6% | 55.3% | ||
| Q2 25 | 69.3% | 51.4% | ||
| Q1 25 | 70.8% | 53.1% | ||
| Q4 24 | 69.0% | 56.9% | ||
| Q3 24 | 69.4% | 53.5% | ||
| Q2 24 | 69.8% | 52.4% |
| Q1 26 | — | -4.9% | ||
| Q4 25 | -9.4% | 2.9% | ||
| Q3 25 | -3.0% | -8.5% | ||
| Q2 25 | -0.3% | -19.3% | ||
| Q1 25 | -13.6% | -14.2% | ||
| Q4 24 | -122.8% | -1.7% | ||
| Q3 24 | -5.6% | -12.6% | ||
| Q2 24 | -3.8% | -20.5% |
| Q1 26 | — | -5.8% | ||
| Q4 25 | -9.8% | 2.6% | ||
| Q3 25 | -2.3% | -6.9% | ||
| Q2 25 | -0.1% | -19.5% | ||
| Q1 25 | -14.3% | -10.2% | ||
| Q4 24 | -121.2% | 0.6% | ||
| Q3 24 | -5.4% | -11.2% | ||
| Q2 24 | -2.3% | -20.1% |
| Q1 26 | — | $-0.05 | ||
| Q4 25 | $-0.45 | $0.03 | ||
| Q3 25 | $-0.10 | $-0.06 | ||
| Q2 25 | $-0.01 | $-0.16 | ||
| Q1 25 | $-0.54 | $-0.08 | ||
| Q4 24 | $-4.69 | $0.01 | ||
| Q3 24 | $-0.21 | $-0.09 | ||
| Q2 24 | $-0.09 | $-0.15 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $964.7M | $1.1B |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $2.4B | $2.1B |
| 总资产 | $5.9B | $7.5B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
| Q1 26 | — | $1.1B | ||
| Q4 25 | $964.7M | $2.9B | ||
| Q3 25 | $1.0B | $3.0B | ||
| Q2 25 | $858.4M | $2.9B | ||
| Q1 25 | $786.2M | $3.2B | ||
| Q4 24 | $1.0B | $3.4B | ||
| Q3 24 | $1.0B | $3.2B | ||
| Q2 24 | $946.8M | $3.1B |
| Q1 26 | — | — | ||
| Q4 25 | — | $3.5B | ||
| Q3 25 | — | $3.5B | ||
| Q2 25 | — | $3.6B | ||
| Q1 25 | — | $3.6B | ||
| Q4 24 | — | $3.6B | ||
| Q3 24 | — | $3.6B | ||
| Q2 24 | — | $3.6B |
| Q1 26 | — | $2.1B | ||
| Q4 25 | $2.4B | $2.3B | ||
| Q3 25 | $2.5B | $2.2B | ||
| Q2 25 | $2.5B | $2.1B | ||
| Q1 25 | $2.4B | $2.3B | ||
| Q4 24 | $2.4B | $2.5B | ||
| Q3 24 | $3.2B | $2.2B | ||
| Q2 24 | $3.2B | $2.1B |
| Q1 26 | — | $7.5B | ||
| Q4 25 | $5.9B | $7.7B | ||
| Q3 25 | $5.9B | $7.6B | ||
| Q2 25 | $5.8B | $7.4B | ||
| Q1 25 | $5.7B | $7.6B | ||
| Q4 24 | $5.9B | $7.9B | ||
| Q3 24 | $6.7B | $7.6B | ||
| Q2 24 | $6.7B | $7.4B |
| Q1 26 | — | — | ||
| Q4 25 | — | 1.55× | ||
| Q3 25 | — | 1.59× | ||
| Q2 25 | — | 1.73× | ||
| Q1 25 | — | 1.56× | ||
| Q4 24 | — | 1.49× | ||
| Q3 24 | — | 1.65× | ||
| Q2 24 | — | 1.76× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $151.7M | $326.8M |
| 自由现金流经营现金流 - 资本支出 | $120.4M | $286.0M |
| 自由现金流率自由现金流/营收 | 13.7% | 18.7% |
| 资本支出强度资本支出/营收 | 3.6% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $356.8M | $608.8M |
8季度趋势，按日历期对齐
| Q1 26 | — | $326.8M | ||
| Q4 25 | $151.7M | $269.6M | ||
| Q3 25 | $219.9M | $146.5M | ||
| Q2 25 | $89.0M | $88.5M | ||
| Q1 25 | $30.8M | $151.6M | ||
| Q4 24 | $47.1M | $230.6M | ||
| Q3 24 | $138.7M | $115.9M | ||
| Q2 24 | $107.1M | $-21.4M |
| Q1 26 | — | $286.0M | ||
| Q4 25 | $120.4M | $205.6M | ||
| Q3 25 | $190.0M | $93.4M | ||
| Q2 25 | $46.7M | $23.8M | ||
| Q1 25 | $-365.0K | $114.4M | ||
| Q4 24 | $10.7M | $182.4M | ||
| Q3 24 | $112.6M | $71.8M | ||
| Q2 24 | $71.2M | $-73.4M |
| Q1 26 | — | 18.7% | ||
| Q4 25 | 13.7% | 12.0% | ||
| Q3 25 | 22.3% | 6.2% | ||
| Q2 25 | 5.8% | 1.8% | ||
| Q1 25 | -0.1% | 8.4% | ||
| Q4 24 | 1.5% | 11.7% | ||
| Q3 24 | 15.9% | 5.2% | ||
| Q2 24 | 10.2% | -5.9% |
| Q1 26 | — | — | ||
| Q4 25 | 3.6% | 3.7% | ||
| Q3 25 | 3.5% | 3.5% | ||
| Q2 25 | 5.2% | 4.8% | ||
| Q1 25 | 4.4% | 2.7% | ||
| Q4 24 | 5.1% | 3.1% | ||
| Q3 24 | 3.7% | 3.2% | ||
| Q2 24 | 5.1% | 4.2% |
| Q1 26 | — | — | ||
| Q4 25 | — | 5.96× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 25.34× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
EXAS
| Screening | $695.1M | 79% |
| Precision Oncology | $183.2M | 21% |
SNAP
暂无分部数据
